Nuveen Quality Municipal Income Fund (NAD)

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #AboutNAD--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today unveils the newly evolved AboutNADⓇ, a centralized educational resource and published research database detailing scientific advancements in NAD+ biology and its role in human health. Guided by the mission of empowering health through scientific education, the new and improved site distills peer-reviewed findin.

The investment case for closed-end funds (CEFs) is weak now due to tight discounts, high leverage costs, and expensive underlying assets. Most CEFs do not deliver sustainable alpha, and lower-fee actively managed ETFs now offer similar exposures with better economics. We have reduced our CEF allocation, favoring alternatives like BDCs, select ETFs, preferreds, and bonds for better value and risk/reward.

NAD offers a high 8% tax-exempt yield, but its share price and NAV have struggled, amid high interest rates and aggressive leverage. The fund's discount to NAV is historically narrow, making current accumulation less attractive compared to its long-term average. Dividend sustainability is questionable, due to inconsistent earnings and reliance on realized gains, raising the risk of a near-term dividend cut.

Fund-level leverage is only attractive when carry or capital gains potential is high; current tight spreads and an inverted yield curve make it less appealing. For tax-exempt CEFs, higher yields often come from longer duration, not leverage; unleveraged long-duration funds or ETFs can offer similar or better yields. Investors should not assume more leverage is always better; careful, situation-specific exposure to fund-level leverage is key to balancing risk and return.

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. These data are expected to support future.

Stocks—especially dividend stocks—have every reason to shoot higher from here. In fact, they have 7 trillion reasons.

One of the only downsides to passive income from stocks and bonds is that the revenue generated from those investments is subject to federal and state income tax.

The credit cycle is arguably deteriorating. Thus, we see investors moving out of corporate credit and into Municipal bonds with hybrid general obligation and revenue exposure. Nuveen Quality Muni Income Fund seems like a prime candidate given its GO and revenue exposure. Moreover, it embodies the excess TEY-treasury spreads on offer. Some might oppose its leveraged strategy due to the effect on its expense ratio and the risks leverage adds in down markets. However, we see lower funding costs emerging.

Evaluating Nuveen Quality Muni Income Fund as an investment due to its current market price and high yield above 8%. NAD's recent price weakness in 2025 appears overdone, presenting a potential buying opportunity. The fund aims to provide income exempt from federal tax and enhance portfolio value.

The stock market has been ugly (particularly growth stocks), and it could get much worse. Thankfully, however, there is another way. Income investing focuses on big, steady dividend and interest payments, thereby allowing investors to worry far less about price volatility (as long as those big income payments keep coming in). This report shares 5 big safe yield strategies (including a variety of top income ideas), and then concludes with an important takeaway about succeeding in this market.

One of the only downsides to passive income from stocks and bonds is that the revenue generated from those investments is subject to federal and state income tax.

New NAD+ Patch, Injection, and Nasal Spray Now Available for Personalized Wellness and Longevity Solutions New NAD+ Patch, Injection, and Nasal Spray Now Available for Personalized Wellness and Longevity Solutions

If you were taking a break from your family on Christmas Day, you may have caught my article on how Jay Powell's recent “hawkish cut” is set to light a fire under high-yielding (and tax-free!) municipal bonds.

We review the CEF market valuation and performance through the third week of December and highlight recent market action. All CEF sectors declined this week due to a more hawkish Fed, with most discounts widening except for the loan sector. The sharp rise in Municipal CEF distributions this year is disproportionate to net income increases, driven by efforts to tighten discounts and deter activists.

Nuveen Quality Municipal Income Fund distributions are only about 52% covered by investment income. NAD is also leveraged, which helped returns in 2024 but may not be an advantage going forward as rates are no longer falling as fast. Nuveen Select Tax-Free Income Portfolio is unleveraged and fully covers its dividends with investment income.

In a challenge brought by competitor PIM Brands, Inc., BBB National Programs' National Advertising Division recommended that General Mills, Inc. discontinue or modify certain express and implied claims regarding the fruit and vegetable content of Mott's Fruit Flavored Snacks and the nutritional benefits of those ingredients. In a challenge brought by competitor PIM Brands, Inc., BBB National Programs' National Advertising Division recommended that General Mills, Inc. discontinue or modify certain express and implied claims regarding the fruit and vegetable content of Mott's Fruit Flavored Snacks and the nutritional benefits of those ingredients.